9.5 Pharmacokinetic and Immunogenicity Assessments Samples for PK and immunogenicity assessments will be collected for all participants r eceiving BMS-986226, as described in Table 9.5-1 through Table 9.5-4 . Immunogenicity samples will be analyzed for anti-BMS -986226 antibodies, by validated immunoassays. All pre-dose samples should be taken within 30 minutes prior to the start of the i nfusion of first drug. End-of infusion (EOI) samples should be taken immediately prior to the stopping of the drug infusion (in monotherapy) or to the stopping of the second drug i nfusion (in combination therapy), preferably within 2 minutes prior to the end of infusion. On-treatment PK samples are intended to be drawn relative to actual dosing days. If a dose occurs on a different day within the cycle due to delays or minor schedule adjustments, PK samples should be adjusted accordingly. If it is known that a dose is going to be delayed, th en the pre-dose sample should be co llected just prior to the delayed dose. However, if a pre-dose sample is collected but the dose is subsequently delayed, an additional pre-dose sample should not be collected.